Literature DB >> 27294581

Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4.

Tadashi Yoshida1, Matsuhiko Hayashi2.   

Abstract

Statins, the inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are potent cholesterol-lowering drugs used for primary and secondary prevention of coronary artery disease. They also possess multiple beneficial effects independent of their cholesterol-lowering properties, which are called as their "pleiotropic" effects. The results of recent studies have revealed that statins exert their pleiotropic effects in the kidneys, in that they are protective against acute kidney injury (AKI). Moreover, Krüppel-like factor 4, a zinc-finger transcription factor, in endothelial cells has been identified as a novel mediator of statins. This article summarizes the pleiotropic effects of statins on AKI, and reviews the recent progress in our understanding of the regulatory mechanisms involved in statin-mediated protection against AKI.

Entities:  

Keywords:  3-Hydroxy-3-methylglutaryl-coenzyme A; Cholesterol; Krüppel-like factors; Pleiotropic effect

Mesh:

Substances:

Year:  2016        PMID: 27294581     DOI: 10.1007/s10157-016-1286-4

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  60 in total

Review 1.  The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes.

Authors:  Kausik K Ray; Christopher P Cannon
Journal:  J Am Coll Cardiol       Date:  2005-10-18       Impact factor: 24.094

2.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

Review 3.  Statins, bone metabolism and treatment of bone catabolic diseases.

Authors:  Yijia Zhang; Aaron D Bradley; Dong Wang; Richard A Reinhardt
Journal:  Pharmacol Res       Date:  2014-01-07       Impact factor: 7.658

4.  Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury.

Authors:  Cristina Quintavalle; Danilo Fiore; Francesca De Micco; Gabriella Visconti; Amelia Focaccio; Bruno Golia; Bruno Ricciardelli; Elvira Donnarumma; Antonio Bianco; Maria Assunta Zabatta; Giancarlo Troncone; Antonio Colombo; Carlo Briguori; Gerolama Condorelli
Journal:  Circulation       Date:  2012-11-12       Impact factor: 29.690

5.  Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion.

Authors:  M Joyce; C Kelly; D Winter; G Chen; A Leahy; D Bouchier-Hayes
Journal:  J Surg Res       Date:  2001-11       Impact factor: 2.192

Review 6.  Preoperative Statin Therapy and Renal Outcomes After Cardiac Surgery: A Meta-analysis and Meta-regression of 59,771 Patients.

Authors:  Jiayang Wang; Chengxiong Gu; Mingxin Gao; Wenyuan Yu; Yang Yu
Journal:  Can J Cardiol       Date:  2015-02-28       Impact factor: 5.223

7.  The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells.

Authors:  Shigeru Morikawa; Wakako Takabe; Chikage Mataki; Toru Kanke; Takahiro Itoh; Youichiro Wada; Akashi Izumi; Yasushi Saito; Takao Hamakubo; Tatsuhiko Kodama
Journal:  J Atheroscler Thromb       Date:  2002       Impact factor: 4.928

8.  KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming during Early Pancreatic Carcinogenesis.

Authors:  Daoyan Wei; Liang Wang; Yongmin Yan; Zhiliang Jia; Mihai Gagea; Zhiwei Li; Xiangsheng Zuo; Xiangyu Kong; Suyun Huang; Keping Xie
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

9.  SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis.

Authors:  X Wang; R Sato; M S Brown; X Hua; J L Goldstein
Journal:  Cell       Date:  1994-04-08       Impact factor: 41.582

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  2 in total

1.  Effect of Rosuvastatin on Acute Kidney Injury in Sepsis-Associated Acute Respiratory Distress Syndrome.

Authors:  Raymond K Hsu; Jonathon D Truwit; Michael A Matthay; Joseph E Levitt; Boyd Taylor Thompson; Kathleen D Liu
Journal:  Can J Kidney Health Dis       Date:  2018-08-02

2.  Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.

Authors:  Niki Katsiki; Maciej Banach; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2020-04-14       Impact factor: 3.318

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.